These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Preparation and Evaluation of the Fully Humanized Monoclonal Antibody GD-mAb Against Respiratory Syncytial Virus. Tian P; Wang Y; Liu H; Yang Y; Wu X; Wei H; Chen T Front Cell Infect Microbiol; 2019; 9():275. PubMed ID: 31417879 [TBL] [Abstract][Full Text] [Related]
10. Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis)-resistant mutants. DeVincenzo JP; Hall CB; Kimberlin DW; Sánchez PJ; Rodriguez WJ; Jantausch BA; Corey L; Kahn JS; Englund JA; Suzich JA; Palmer-Hill FJ; Branco L; Johnson S; Patel NK; Piazza FM J Infect Dis; 2004 Sep; 190(5):975-8. PubMed ID: 15295704 [TBL] [Abstract][Full Text] [Related]
11. Respiratory syncytial virus persistence in the lungs correlates with airway hyperreactivity in the mouse model. Estripeaut D; Torres JP; Somers CS; Tagliabue C; Khokhar S; Bhoj VG; Grube SM; Wozniakowski A; Gomez AM; Ramilo O; Jafri HS; Mejias A J Infect Dis; 2008 Nov; 198(10):1435-43. PubMed ID: 18828742 [TBL] [Abstract][Full Text] [Related]
12. Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. Wu H; Pfarr DS; Johnson S; Brewah YA; Woods RM; Patel NK; White WI; Young JF; Kiener PA J Mol Biol; 2007 May; 368(3):652-65. PubMed ID: 17362988 [TBL] [Abstract][Full Text] [Related]
13. Respiratory syncytial virus disease: update on treatment and prevention. Krilov LR Expert Rev Anti Infect Ther; 2011 Jan; 9(1):27-32. PubMed ID: 21171875 [TBL] [Abstract][Full Text] [Related]
14. Respiratory syncytial virus fusion nanoparticle vaccine immune responses target multiple neutralizing epitopes that contribute to protection against wild-type and palivizumab-resistant mutant virus challenge. Gilbert BE; Patel N; Lu H; Liu Y; Guebre-Xabier M; Piedra PA; Glenn G; Ellingsworth L; Smith G Vaccine; 2018 Dec; 36(52):8069-8078. PubMed ID: 30389195 [TBL] [Abstract][Full Text] [Related]
15. Development of bioluminescence imaging of respiratory syncytial virus (RSV) in virus-infected live mice and its use for evaluation of therapeutics and vaccines. Fuentes S; Arenas D; Moore MM; Golding H; Khurana S Vaccine; 2017 Jan; 35(4):694-702. PubMed ID: 27989627 [TBL] [Abstract][Full Text] [Related]
17. Resveratrol suppresses persistent airway inflammation and hyperresponsivess might partially via nerve growth factor in respiratory syncytial virus-infected mice. Zang N; Li S; Li W; Xie X; Ren L; Long X; Xie J; Deng Y; Fu Z; Xu F; Liu E Int Immunopharmacol; 2015 Sep; 28(1):121-8. PubMed ID: 26044349 [TBL] [Abstract][Full Text] [Related]
18. Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children. Andabaka T; Nickerson JW; Rojas-Reyes MX; Rueda JD; Bacic Vrca V; Barsic B Cochrane Database Syst Rev; 2013 Apr; (4):CD006602. PubMed ID: 23633336 [TBL] [Abstract][Full Text] [Related]
19. Respiratory syncytial virus infections in children. Staat MA Semin Respir Infect; 2002 Mar; 17(1):15-20. PubMed ID: 11891515 [TBL] [Abstract][Full Text] [Related]
20. Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis. Robinson KA; Odelola OA; Saldanha I; McKoy N Cochrane Database Syst Rev; 2010 Feb; (2):CD007743. PubMed ID: 20166098 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]